Highbridge Capital Management’s Halozyme HALO Stock Holding History

Highbridge Capital Management’s Portfolio HALO Stock Details HALO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2017 Q1	–	Sell	-21,770	Closed	-$215K	–	1527
2016 Q4	$215K	Buy	+21,770	New	+$238K	﹤0.01%	1098
2015 Q4	–	Sell	-46,849	Closed	-$629K	–	1603
2015 Q3	$629K	Buy	+46,849	New	+$941K	0.01%	949
2013 Q3	–	Sell	-33,119	Closed	-$263K	–	1379
2013 Q2	$263K	Buy	+33,119	New	+$211K	﹤0.01%	1087

Other funds holding HALO

Third Security Radford, Virginia $241M AUM 45.43% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

IAM

Iridian Asset Management Westport, Connecticut $247M AUM 20.65% 1-Year Est. Return

BB Biotech Schaffhausen, Switzerland $3.98B AUM 15.47% 1-Year Est. Return

First Eagle Investment Management New York $59B AUM 32.99% 1-Year Est. Return

Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Highbridge Capital Management's HALO Position: Q1 2017 in Review

Highbridge Capital Management sold out of Halozyme (HALO) in Q1 2017, closing a stake of 21,770 shares — an estimated $215K sold.

Highbridge Capital Management first reported a position in HALO in Q2 2013 and held it in 3 quarters. The position peaked at $629K in Q3 2015. 160 funds tracked by Wall St. Rank hold HALO as of Q1 2017.

Highbridge Capital Management reported no remaining Halozyme position as of Q1 2017 after selling out during the quarter.
Highbridge Capital Management sold 21,770 Halozyme shares in Q1 2017, an estimated $215K.
Highbridge Capital Management first reported a position in Halozyme in Q2 2013 and held it in 3 quarters.
Highbridge Capital Management's Halozyme position peaked at $629K in Q3 2015.
160 funds tracked by Wall St. Rank held Halozyme as of Q1 2017.

Based on Highbridge Capital Management's 13F filing for Q1 2017, filed 15 May 2017.